Diagnostic Value of JC Polyomavirus Viruria, Viremia, Serostatus and microRNA Expression in Multiple Sclerosis Patients Undergoing Immunosuppressive Treatment
Permanent link
https://hdl.handle.net/10037/25065Date
2022-01-11Type
Journal articleTidsskriftartikkel
Peer reviewed
Author
Prezioso, Carla; Ciotti, Marco; Brazzini, Gabriele; Piacentini, Francesca; Passerini, Sara; Grimaldi, Alfonso; Landi, Doriana; Nicoletti, Carolina Gabri; Zingaropoli, Maria Antonella; Iannetta, Marco; Altieri, Marta; Conte, Antonella; Limongi, Dolores; Marfia, Girolama Alessandra; Ciardi, Maria Rosa; Mastroianni, Claudio Maria; Palamara, Anna Teresa; Moens, Ugo; Pietropaolo, ValeriaAbstract
Markers of JC polyomavirus (JCPyV) activity can be used to evaluate the risk of progressive
multifocal leukoencephalopathy (PML) in treated multiple sclerosis (MS) patients. The presence of
JCPyV DNA and microRNA (miR-J1-5p), the anti-JCV index and the sequence of the non-coding
control region (NCCR) in urine and plasma were determined in 42 MS subjects before treatment (T0),
6 months (T6) and 12 months (T12) after natalizumab, ocrelizumab, fingolimod or dimethyl-fumarate
administration and in 25 healthy controls (HC). The number of MS patients with viruria increased
from 43% at T0 to 100% at T12, whereas it remained similar for the HC group (35–40%). Viremia
first occurred 6 months after treatment in MS patients and increased after 12 months, whereas it was
absent in HC. The viral load in urine and plasma from the MS cohort increased over time, mostly
pronounced in natalizumab-treated patients, whereas it persisted in HC. The archetypal NCCR was
detected in all positive urine, whereas mutations were observed in plasma-derived NCCRs resulting
in a more neurotropic variant. The prevalence and miR-J1-5p copy number in MS urine and plasma
dropped after treatment, whereas they remained similar in HC specimens. Viruria and miR-J1-5p
expression did not correlate with anti-JCV index. In conclusion, analyzing JCPyV DNA and miR-J1-5p
levels may allow monitoring JCPyV activity and predicting MS patients at risk of developing PML.
Publisher
MDPICitation
Prezioso C, Ciotti M, Brazzini G, Piacentini F, Passerini, Grimaldi, Landi, Nicoletti, Zingaropoli, Iannetta, Altieri, Conte A, Limongi, Marfia, Ciardi, Mastroianni, Palamara AT, Moens u, Pietropaolo V. Diagnostic Value of JC Polyomavirus Viruria, Viremia, Serostatus and microRNA Expression in Multiple Sclerosis Patients Undergoing Immunosuppressive Treatment. Journal of Clinical Medicine. 2022;11(2)Metadata
Show full item recordCollections
Copyright 2022 The Author(s)